New Delhi, Aug 20: The American-based pharma main Johnson & Johnson (J&J) has utilized to the Central Medicine Normal Management Organisation (CDSCO) for permission to conduct a vaccine trial of the Covid-19 single shot Janssen vaccine in India on kids of 12-17 age group.
The American pharma J&J stated in an announcement that it had submitted its utility on Tuesday, and that it's "imperative" to make sure all sections of the inhabitants, together with kids, are vaccinated in opposition to the coronavirus as rapidly as doable to cease the virus.
COVID-19 Vaccine Update: Johnson & Johnson's Single-Dose Coronavirus Vaccine Will get Emergency Use Approval in India.
The one-shot vaccine of J&J is the second Covid-19 vaccine which has already been authorised for the Emergency Use Authorisation (EUA) via the fast-track approval route by the Drug Controller Common of India.
Within the assertion, Johnson & Johnson India additionally stated this was an vital step ahead in accelerating the provision of its Covid-19 vaccine to assist finish the pandemic.
Earlier, the Union {Health} Minister Mansukh Mandaviya had tweeted concerning the Emergency Use Authorisation being given to Johnson & Johnson.
Mandaviya had tweeted, "India expands its vaccine basket! Johnson and Johnson's single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines. This will further boost our nation's collective fight against COVID19."
The 5 vaccines which have been granted emergency use authorization approval in India embody Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V, Moderna and now Johnson & Johnson (J&J).
(The above story first appeared on SociallyTrend on Aug 20, 2021 01:18 PM IST. For more news and updates on politics, world, sports activities, entertainment and life-style, go surfing to our web site latestly.com).
